trans

480 INDEX
calcium-binding proteins, 245, 251, 252, 253
chemotherapy, 439, 440–1, 442, 443, 444, 445
drug resistance, 401, 402, 406, 439, 443
chloroquine resistance, 401
molecular basis, 402
cyclin-dependent kinases (CDKs), 272–3
energy metabolism, 154, 155–65
branching pathways, 160–1
electron transport, 161–3
glycolysis, 156, 158–60
hexose monophosphate shunt, 160
mitochondrial, 161–5
nutrient uptake, 155, 156, 157
genome, 21–2, 26, 154
apicoplast, 287, 289
physical mapping, 8
glutamine uptake, 173
guanylyl cyclase activity, 262–4
laboratory studies, 91
life cycle, 106
mitochondrial metabolism, 281
mitogen-activated protein (MAP) kinases, 268,
269
proteasome, 177, 178, 180
protein phosphatases, 273–4
proteolytic enzymes, 175, 176, 177, 179
therapeutic targets, 181–2
purine metabolism, 209–11
transport, 201–2
rifin genes, 22
RNA post-transcriptional processing, 86
var genes, 22, 58
Plasmodium galinaceum:
energy metabolism, 161
RNA post-transcriptional processing, 86
Plasmodium knowlesi:
acidocalcisomes, 249
major variant erythrocyte surface proteins, 107
Plasmodium lophurae:
amino acid metabolism, 192
apicoplast genome, 287
Plasmodium malariae,22
Plasmodium ovale, 441
chemotherapy, 442, 443, 444
Plasmodium vivax, 106, 441
chemotherapy, 442, 444
drug resistance, 405, 440, 443
chloroquine resistance, 405
dhfr mutations, 409
genome, 22
major variant erythrocyte surface proteins, 107
Plasmodium yoelii:
energy metabolism, 163
RNA post-transcriptional processing, 86
Plastids, 277, 286–7
endosymbiosis theory, 277–9
evolutionary origins, 287
genome, 278, 287, 289
intracellular gene transfer to nucleus, 287
see also Apicoplast
Platyhelminths, 438
chemotherapy, 458–60
see also Antihelmintics
class II protein coding gene transcription,
59
expressed sequence tag (EST) datasets, 9
genomes, 4, 20, 25–6
RNA trans-splicing, 31
Pneumocystis carinii pneumonia, 449
Poly(A) binding protein, 70, 84
Poly(A) polymerase, 75
Poly(A) tail, 70
RNA degradation pathways, 71, 83
Polyadenylation, 75–6
Polyamines:
synthesis, 189–91
therapeutic targets, 189
Polycistronic transcription, 35–7, 48–9, 57, 73
Polystoma nearcticum, 392
Posaconazole (SCH56592), 423
Post-transcriptional regulation, 67–87
eukaryotic model systems, 69–73
kinetoplastids, 73–85
effects of protein synthesis inhibition,
80
heat shock gene control, 80–1
3-untranslated regions, 78–80
protein degradation/modification, 72–3,
85
RNA cytosolic localization, 70
RNA decay, 71–2
RNA export to cytosol, 69–70
RNA processing, 69
therapeutic targets, 86–7
translation, 70
Praziquantel, 426, 458–9, 460
mode of action, 303, 306, 459
resistance, 427
structure, 427
Prednisone, 446
Primaquine, 411, 442, 443, 444–5
resistance, 411–12